机构投资者增持 Solventum 的股份，分析师评级脾缓不一，一致认为“持有”。 Institutional investors boost stakes in Solventum, amid mixed analyst ratings and a consensus "Hold."

MetLife投资管理公司和其他一些机构投资者增加了对Solveentum公司(一家拥有四个商业部分的保健公司)的股份。 MetLife Investment Management and several other institutional investors increased their stakes in Solventum Co., a healthcare company with four business segments. Mizuho以中立的评分和70美元的价格目标启动了覆盖范围,而其他公司则有不同的评分和目标,导致协商一致的“坚持”和68.29美元的目标价格。 Mizuho initiated coverage with a neutral rating and a $70 price target, while other firms have varied ratings and targets, leading to a consensus "Hold" with a $68.29 target price. 索尔文图的股价在一年低点47.16美元和高点96.05美元之间. Solventum's stock ranges between a 1-year low of $47.16 and a high of $96.05.